The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

The STAND Act (HR 6835) expands spinal cord injury care via annual preventive evaluations and improved access to prosthetics and assistive mobility devices for eligible veterans. The Travel Assistance ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

Increasing frontline covalent BTK inhibitor use and emerging BTKi+BCL2i+anti-CD20 triplets constrain the R/R BTK-naïve ...

As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...